ABSTRACT-We examined whether nasal hyperresponsiveness to leukotriene (LT) D4 is seen in our allergic rhinitis model, which showed sneezing and biphasic nasal blockage by repeated antigen inhalation challenge, and whether a dilatation of mucosal blood vessels contributes to this hyperresponsiveness. Nasal blockage [increase of specific airway resistance (sRaw)] was indexed as nasal (hyper)responsiveness. The sensitized -challenged guinea pig showed a remarkable dose-dependent increase in sRaw by intranasal instillation of LTD 4 (10 m l /nostril) at 10 -10 to 10 -6 M 10 h and 2 days but not 7 days after the challenge. The increase in sRaw induced by LTD4 was largely blocked by pranlukast or naphazoline, and this was dosedependently suppressed by N M -nitro-L-arginine methyl ester. Sodium nitroprusside induced an elevation of sRaw in the sensitized -challenged animal in the hyperresponsiveness state, but the degree did not differ from that in the non-sensitized -non-challenged group. The amount of NO2
Cysteinyl leukotrienes (CysLTs: LTC4, LTD4 and LTE4) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. It has been reported that CysLTs were detected in the nasal washings following antigen challenge of subjects with allergic rhinitis (1, 2) and that treatment with a 5-lipoxygenase inhibitor and a CysLT1-receptor antagonist modified allergen-induced nasal mucosa swelling via dilatation of nasal capacitance blood vessel and increases in nasal capillary permeability (3 -5) , suggesting that CysLTs act as significant inflammatory mediators in allergic rhinitis and that allergen-induced vascular changes are predominantly induced by CysLTs.
To date, clinical examinations revealed that allergic rhinitis patients show obviously increased nasal blockage in response to topical LTD4, a phenomenon known as nasal hyperresponsiveness (6 -8) . On the other hand, although very high doses of topical LTD 4 have been reported to increase either nasal blockage or nasal vascular permeability in non-sensitized animals (9, 10), it has not been determined whether a higher response to the agonist occurs in the allergic rhinitis model. Due to the limitation of clinical research and insufficient information obtained from normal animals, the mechanism of nasal hyperresponsiveness to LTD4 in allergic rhinitis patients remains unclear. The use of an experimental allergic rhinitis model that closely resembles the human case indispensably resolves such drawbacks in the analysis of the nasal hyperresponsiveness to LTD4.
Recently, we reported an allergic rhinitis model that showed anaphylactic biphasic elevation of specific airway resistance (sRaw) (11) and considerable nasal hyperresponsiveness to histamine following repetitive quantitative inhalation challenge using Japanese cedar pollen in the guinea pig (12) . Furthermore, these symptoms in this model are similar to those observed in clinical situations, indicating that our model is extremely effective in determining whether hyperresponsiveness to LTD4 is also observed.
In the present study, we first evaluated the effect of pranlukast, a CysLT1-receptor antagonist, on biphasic elevation of sRaw induced by the antigen challenge in the sensitized -challenged guinea pig. Then, we examined whether repetitive inhalations of antigen in the sensitizedchallenged guinea pig lead to nasal hyperresponsiveness to LTD4 and whether dilatation of the mucosal blood vessel contributes to the nasal hyperresponsiveness.
MATERIALS AND METHODS

Animals
Male, 3-week-old, Hartley guinea pigs weighing 250 -300 g were purchased from Japan SLC, Hamamatsu. The animals were housed in a temperature-controlled room at 23 ± 1°C and 60 ± 10% humidity, illuminated from 08:00 -20:00 h. They were fed a standard laboratory diet and given water ad libitum. The first sensitization was started after 2 weeks.
This animal study was approved by the Experimental Animal Research Committee of Kyoto Pharmaceutical University.
Reagents
Reagents and their sources were as follows: LTD4 and pranlukast hemihydrate (Ono Pharm., Co., Ltd., Osaka); AA-861 (donated from the laboratory of Takeda Chem. Ind., Osaka); indomethacin, mepyramine maleate, naphazoline hydrochloride, N M -nitro-L-arginine methyl ester (L-NAME) hydrochloride, N M -nitro-D-arginine methyl ester (D-NAME) hydrochloride, L-arginine hydrochloride and sodium nitroprusside (SNP) dihydrate (Sigma Chem., St. Louis, MO, USA); Evans blue (Merck, Darmstadt, Germany); sodium pentobarbital (Abbott Lab, North Chicago, IL, USA); methylcellulose and polyoxyethylene [20] sorbitan monolaurate (Wako Pure Chem., Osaka); and lidocaine hydrochloride (Fujisawa Pharm. Co. Ltd., Osaka). All other reagents used were the highest grade of commercial products available.
LTD4 in physiological saline containing 0.5% ethanol and SNP in physiological saline were prepared. Pranlukast, mepyramine and indomethacin were suspended in 0.5% methylcellulose, AA-861 was suspended in physiologic saline containing 1% polyoxyethylene [20] sorbitan monolaulate and all other drugs were dissolved in physiological saline.
We harvested the Japanese cedar (Cryptomeria japonica) pollens. Al(OH)3 gels were prepared from 0.5 M NaOH and 1/12 M Al2(SO4)3 as previously described (13) .
Preparation of Japanese cedar pollen extracts
Cedar pollen extracts used for sensitization were prepared as previously described (11) . In brief, pollens were suspended in physiologic saline at 100 mg/ml and allowed to stand at 4°C for 18 h under mild stirring. The suspension was then centrifuged (1,700´g, 15 min), and the resultant supernatant was used as the sensitization antigen; this was stored at -80°C until use. The protein concentration in the solution was estimated to be 500 mg protein /ml according to the method of Bensadoun and Weinstein (14) .
Sensitization and challenge
As previously described (11), bilateral intranasal sensitization of guinea pigs was induced by the instillation of cedar pollen extracts adsorbed on Al(OH)3 gel of 0.3 mg protein · 0.3 mg Al(OH)3 -1 · 3 ml -1 per each nostril 2 times a day for 7 days. Prior to each sensitization, the upper airway mucosal surface was topically anesthetized by subjecting the animal to a 5-min inhalation of a 4% lidocaine hydrochloride mist, which was generated with an ultrasonic nebulizer (NE-U12; Omron, Osaka). This procedure, providing effective sensitization by prolonged retention of the antigen Al(OH)3 in the nasal cavity, was employed based on the research findings that lidocaine reduces the ciliary beat frequency of the guinea pig airway in vitro (15) and that topical anesthetic drugs do not decrease mucosal absorbency (16) . Then, the sensitized animal was bilaterally intranasally challenged once every week by quantitative inhalation of the cedar pollen at a dose of 1.8 mg /each nostril using a hand-made inhalation apparatus (Fig. 1) . Upon application of the pollen to both nostrils of the spontaneously breathing guinea pig, almost all inhaled pollens were trapped in the upper airways (17) . Four groups of guinea pigs were employed for the experiments: non-sensitized -non-challenged; sensitizedchallenged; sensitized -non-challenged; non-sensitizedrepeatedly challenged (2 days after the 7th antigen inhalation challenge without sensitization).
Effects of drugs on the biphasic increased sRaw induced by pollen inhalation challenge Pranlukast (30 mg / kg, p.o.), a CysLT1-receptor antagonist, and mepyramine (10 mg/kg, p.o.), an H1-receptor antagonist, were administered 1 h before the 4th pollen inhalation challenge. sRaw was measured before and 10 min, 1, 2, 3, 4, 6, 8 and 10 h after the pollen challenge. The respective magnitudes of the early and late responses were calculated as the area under the response curve (AUC) from 0 (before) to 3 h and 3 to 10 h after antigen challenge of vehicle-or drug-treated animals.
Nasal sRaw responsiveness to LTD 4 and SNP
The following five examinations were carried out to evaluate nasal airway responsiveness to LTD4 and SNP in the conscious guinea pig. Either 10 m l/ nostril of LTD4 or SNP was instilled, and sRaw was indexed as nasal airway responsiveness. Non-sensitized -non-challenged guinea pigs acted as controls in some experiments. 1) Time-course changes in sRaw elevation by LTD4 and SNP: a fixed concentration of LTD4 (10 -8 M) or SNP (10 -6 M) was applied to the sensitized -challenged animal 2 days after the 20th or 30th pollen inhalation challenge, and sRaw was monitored for the subsequent 120 min or 10 min. 2) Occurrence and disappearance of sRaw elevation by LTD4 after an antigen inhalation challenge: various doses of LTD4 (10 -12 -10 -6 M) were instilled at 20-min intervals to the sensitizedchallenged animal 10 h, 2 days or 7 days after the 20th pollen inhalation challenge. sRaw was measured 10 min after the respective instillations. 3) Dose-sRaw responsiveness to SNP: various doses of SNP (10 -10 -10 -2 M) were instilled at 10-min intervals to the sensitized -challenged animal 2 days after the 30th pollen inhalation challenge. sRaw was measured 2 min after the respective instillations. 4) Change in sRaw elevation by LTD4 in response to increased number of pollen inhalation challenges: a fixed dose of LTD4 (10 -8 M) was instilled to the sensitizedchallenged animal 2 days after the respective 1st to 30th pollen inhalation challenges. sRaw was measured 10 min after instillation. 5) Influence of sensitization without challenge or non-sensitization -pollen inhalation challenge on nasal responsiveness to LTD4: two doses of LTD4 (10 -8 and 10 -6 M) were instilled at 20-min intervals to the sensitizednon-challenged or to the non-sensitized -repeatedly challenged animal.
In the text, "hyperresponsiveness" indicates the state that the sensitized -challenged animal showed significantly elevated sRaw (nasal blockage) induced by intranasal LTD4 or agonist instillation.
Measurement of sRaw
sRaw was measured by a two-chambered, double-flow plethysmograph system according to the method of Pennock et al. (18) . In brief, the animal was placed with its neck extended through the partition of a two-chambered box, and sRaw was measured using the Data analyzer Pulmos-I (M.I.P.S., Osaka) and a PC 9801 FA computer (NEC, Tokyo) after detection of the airflow by sensors attached to both the front and rear chambers.
Measurement of the change in diameter of the nasal blood vessel
Time-course change in the diameter of nasal blood vessels following application of LTD4 solution onto the nasal mucosa was evaluated 2 days after the 30th pollen inhalation challenge in the sensitized -challenged guinea pig.
Non-sensitized -non-challenged and sensitized -challenged guinea pigs were anesthetized by sodium pentobarbital (40 mg / kg, i.p.) and set on a heating pad to avoid any decrease in body temperature. Nasal mucosa was exposed surgically and observed under a stereoscopic microscope (SZX12; Olympus Optical Co., Ltd., Tokyo) at a magnification of 50. Ten microliters of LTD4 (10 -8 M) was dropped onto the exposed mucosal surface followed by observation for 40 min. Nasal mucosa was photographed by a camera (C-35AD-4, Olympus Optical Co., Ltd.) equipped with the microscope, before and 2, 5, 10, 20 and 40 min after LTD4 application. The main blood vessels in the mucosa on the photographs were veins, which were 50 -80 mm in diameter before the LTD4 application and formed irregular networks. The diameters of the randomly selected veins were measured before and after the application.
Measurement of the change of vascular permeability
Plasma extravasation into the nasal tissue as a result of LTD4 instillation was evaluated. Evans blue (10 mg · ml -1 · kg -1 , i.v.) was administered to the sensitized -challenged guinea pig 2 days after the 30th pollen inhalation challenge. One hour later, 10 -8 M LTD4 was instilled into both nasal cavities in the same manner as described above. Ten or forty minutes after the instillation, the guinea pig was sacrificed by exsanguination under pentobarbital anesthesia (40 mg/ kg, i.v.). To quantify the dye in the nasal tissue, nasal mucosal tissue was removed after perfusion of the head using 40 ml /animal of saline through both the right and left carotid arteries. The tissue was treated with an alkaline solution (1.2 M KOH, 37°C for 18 h, 2 ml/ animal), the suspension was centrifuged at 1,700´g for 10 min, and the dye in the supernatant was calorimetrically measured at 620 nm, according to the method of Katayama et al. (19) . Non-sensitized -non-challenged -saline-instilled and non-sensitized -non-challenged -LTD4-instilled groups acted as controls.
Effects of drugs on the increased sRaw induced by LTD4
Pranlukast (30 mg / kg, p.o.), a CysLT1-receptor antagonist, was administered 1 h before the application of LTD4 (10 -8 M) on the 2nd day after the 20th antigen challenge. sRaw was measured 10 min after LTD4 instillation.
On the 2nd day after the 20th antigen challenge, naphazoline (0.1 mg/kg, i.v.), an a-stimulant, was administered 8 or 35 min after the application of LTD4 (10 -8 M). sRaw was measured immediately before and 2 or 5 min after astimulant treatment.
L-NAME (3, 10 and 30 mg/kg, i.v.), a nitric oxide (NO) synthase inhibitor, or its inactive enantiomer D-NAME (10 mg/ kg, i.v.) was administered 15 min before LTD 4 instillation on the 2nd day after the 20th challenge. Furthermore, in order to investigate the reversal effect of L-arginine on L-NAME-induced suppression of LTD4-induced sRaw elevation, L-arginine (600 mg/kg, i.v.) was coadministered with L-NAME 15 min before LTD4 instillation. sRaw was measured 10 min after LTD4 instillation.
On the 2nd day after the 20th challenge, indomethacin (10 mg/ kg, p.o.), a cyclooxygenase (COX) inhibitor, and AA-861 (100 mg/kg, i.p.), a 5-lipoxygenase (5-LO) inhibitor, were administered 1 h and 30 min, respectively, before LTD4 instillation.
Measurement of NO2
-and NO3 -in nasal cavity lavage fluid (NCLF)
The NCL was conducted according to the previously described method (17) in sensitized -challenged and non-sensitized -non-challenged guinea pigs. Briefly, after anesthetization with sodium pentobarbital (40 mg/ kg, i.p.), one end of the silicone tubing, the other end of which was connected to an air pump, was properly positioned in the right nostril under reduced pressure by the air pump; then 1 ml saline prewarmed at 37°C was aspirated from the left nostril via a tube.
Three initial NCLs were performed to remove pre-existing NO 2 -and NO3 -at 20-min intervals to non-sensitizednon-challenged or sensitized -challenged guinea pigs, and the 3rd NCLF served as a baseline. LTD4 (10 -8 M) was intranasally instilled 10 min after the 3rd NCL and then NCL was performed 10 min after the LTD4 instillation.
The NCLF recovered was centrifuged at 10,000 r.p.m. for 40 min at 4°C. The resultant supernatant was used for the NO 2 -and NO3 -assay. The amounts of NO2 -and NO3 -was measured by NO2 -and NO3 -assay kit-F (fluorometric) (Dojindo Lab. Co., Ltd., Kumamoto).
Statistical analyses
Statistical analyses were performed by one-way analysis of variance (ANOVA). Individual group differences were determined by Bonferroni's multiple test when a significant difference was detected. Comparison of the amounts of NO 2 -and NO3 -before and after LTD4 instillation were performed by the paired t-test. Statistical significance was established at the P<0.05 level.
RESULTS
Effects of pranlukast and mepyramine on the biphasic increased sRaw induced by the pollen inhalation challenge
When the effects of pranlukast and mepyramine on the increase in sRaw at the early and late phases induced by the 4th challenge were compared by AUCs, pranlukast effectively suppressed the late sRaw elevation, but did not influence the early response. On the other hand, mepyramine inhibited neither the early nor the late sRaw elevation (Fig. 2) . Similar results were also observed at the 7th, 10th Fig. 2 . Effect of pranlukast and mepyramine on the area under the response curve (AUC) for the increase in specific airway resistance (sRaw) at the early (0 -3 h) (a) and late (3 -10 h) (b) phase after inhalation challenge using cedar pollen in the sensitized -challenged guinea pig. The experiment was performed at the 4th cedar pollen inhalation challenge. Pranlukast (30 mg /kg) and mepyramine (10 mg/kg) were administered orally 1 h before the inhalation challenge. Data represent the mean ± S.E.M. of 12 animals. Open column: nonsensitized -non-challenged, closed column: sensitizedchallenged, striped column: sensitized -challengedpranlukast-treated, shaded column: sensitized -challenged -mepyramine-treated. **P<0.01 compared to the sensitized -challenged group. † † P<0.01, compared to the non-sensitized -non-challenged group.
and 13th challenges (data not shown).
Time-course changes in sRaw after LTD4 instillation and nasal responsiveness to LTD4 after the pollen inhalation challenge Figure 3A shows the time-course change in sRaw after instillation of 10 -8 M LTD4 into both nasal cavities of the sensitized-challenged guinea pig 2 days after the 20th pollen inhalation challenge. Instillation of LTD4 caused a swift elevation of sRaw that peaked at 10 min followed by a diminution at 20 min. However, a moderate increase in sRaw was still recognized at 20 to 120 min. sRaw was consequently measured 10 min after LTD4 instillation in the following experiments.
Nasal responsiveness of the sensitized-challenged guinea pig to LTD4 was evaluated 10 h, 2 days and 7 days after the 20th antigen challenge and compared to that of the non-sensitized -non-challenged group. In the sensitizedchallenged animal, 10 -12 M LTD4 tended to elevate sRaw, and dose-dependent increases were recognized at 10 -10 to 10 -6 M, with the increases being significant at 10 h and 2 days after the antigen challenge, whereas the nonsensitized -non-challenged animal showed no sRaw increase by the agonist at 10 -6 M. However, this outstanding hyperresponsiveness almost disappeared on the 7th day (Fig. 3B) .
Throughout the above experiments, no significant differences were found between the sRaw of the two groups before LTD4 instillation: mean ± S.E.M. of sRaw values 10 h, 2 days and 7 days after the 20th antigen challenge in the sensitized-challenged and non-sensitized -non-challenged groups were 1.72 ± 0.22 and 1.58 ± 0.15, 1.51 ± 0.13 and 1.58 ± 0.15, and 1.59 ± 0.13 and 1.50 ± 0.13 (n = 12) cmH2O´ml/ (ml /s), respectively. Nasal responsiveness to LTD4 during the course of repetitive challenges Figure 4 shows the results of nasal responsiveness to 10 -8 M LTD4 two days after the respective 1st -30th pollen challenges in the sensitized -challenged guinea pig. Although no increase in sRaw was observed in the sensitized -challenged group at the 1st pollen inhalation challenge, significant hyperresponsiveness was obtained at the 4th pollen challenge. The degree of hyperresponsiveness was elevated at an antigen-challenging time-dependent fashion until the 30th antigen challenge.
Influence of sensitization-pollen inhalation challenge and non-sensitization-pollen inhalation challenge on nasal responsiveness to LTD 4 In sensitized -challenged animals, a dose-dependent increase was recognized at 10 -8 and 10 -6 M LTD4 2 days after the 7th antigen challenge, which was significant in comparison with the non-sensitized -non-challenged group. The non-sensitized -repeatedly challenged and sensitizednon-challenged animals also showed dose-dependent increases in sRaw in response to LTD4, but their magnitudes were marginal and not significantly different from the nonsensitized -non-challenged group (Fig. 5) .
Effect of pranlukast on the increased sRaw induced by LTD4 Figure 6A shows the effect of pranlukast on the increased sRaw induced by LTD4 instillation. When pranlukast (30 mg / kg, p.o.) was administered 1 h before LTD4, sRaw elevation was potently suppressed to a level similar to that of the non-sensitized -non-challenged group.
Effect of naphazoline on the increased sRaw induced by LTD 4 Intravenous naphazoline dramatically lowered spontaneous sRaw in both the non-sensitized -non-challenged and sensitized -challenged groups. Meanwhile, the increased sRaw induced by LTD 4 (10 -8 M) appeared to be completely blocked and was further lowered to below normal levels at 10 and 40 min after LTD4 instillation by the drug. However, the reduced levels of sRaws in response to naphazoline at 10 and 40 min after LTD4 application did not reach the level of sRaw after naphazoline in the non-sensitized -nonchallenged and/ or sensitized -challenged group without LTD4; the reduced sRaw in response to naphazoline at 10 min after the LTD4 nasal drop was not significant, whereas that at 40 min was significantly weaker than the level in the non-sensitized -non-challenged group (Fig. 6B) .
Intranasal administration (10 ml / nostril, 10 -4 M) of naphazoline induced a dramatic lowering of spontaneous sRaw and was comparable to that by intravenous administration (0.1 mg /kg) in the non-sensitized -non-challenged animals: changes in sRaw 5 min after the intranasal and intravenous treatment were -0.54 ± 0.13 (n = 5) and -0.52 ± 0.11 (n = 5) cmH2O´ml/ (ml /s), respectively. The effect of intranasal naphazoline on the sRaw elevation induced by LTD4 was unreliable because of the elimination of naphazoline from the nasal cavity by the increased secretion of the nasal discharge by LTD4. Time-course changes in the diameter of nasal blood vessels due to LTD4 application Figure 7A shows the time-course changes in the diameter of blood vessels due to exposure to 10 -8 M LTD4. LTD4 application caused a swift dilatation of the vessels, which peaked at 10 min, followed by recovery at 40 min to the same level as that before the drop in LTD4. In the nonsensitized -non-challenged-LTD4-instilled group, no changes were observed at any time. Figure 7B represents the stereoscopic microscope pictures of nasal blood vessels in the sensitized -challenged animal: before (a) and 10 min after LTD4 instillation (b).
Nasal vascular permeability response to LTD4 Table 1 shows the nasal vascular permeability induced by 10 -8 M LTD4. When LTD4 was instilled into the nasal cavities of the non-sensitized -non-challenged guinea pigs, no increase in the amount of dye in the nasal tissue was observed. However, LTD 4 instilled in the sensitized -challenged group induced a significant increase in vascular permeability, which returned to the normal (non-sensitizednon-challenged-saline-instilled group) level 40 min after the LTD4 instillation.
Effect of L-NAME on the increased sRaw induced by LTD4
Effect of L-NAME on the increased sRaw induced by LTD4 instillation is shown in Fig. 8a . Increased sRaw due to LTD 4 instillation in the sensitized -challenged group was dose-dependently inhibited by pretreatment with L-NAME (3 -30 mg/ kg, i.v.), but not with D-NAME (10 mg/ kg, i.v.). However, as shown in Table 2 , neither L-NAME nor L-arginine affected baseline sRaw. Figure 8b shows the reversal effect of L-arginine (600 mg/ kg, i.v.) on L-NAME (10 mg/ kg, i.v.)-induced , i.v.) administration on the 2nd day after the 30th pollen inhalation. Data are the mean ± S.E.M. from 10 animals. *P<0.05, compared to the non-sensitized -non-challenged -saline-instilled group. † P<0.05, compared to the nonsensitized -non-challenged -LTD4-instilled group. N.D.: not determined.
Fig. 8. Effect of N
M -nitro-L-arginine methyl ester (L-NAME) and N M -nitro-D-arginine methyl ester (D-NAME) on leukotriene (LT) D4-induced increase of specific airway resistance (sRaw) (a) and reversal effect of L-arginine on L-NAME-induced suppression (b) in the sensitized -challenged guinea pig. sRaw was measured 10 min after LTD4 instillation. The experiment was performed 2 days after the 20th cedar pollen inhalation challenge. L-NAME (3, 10 and 30 mg /kg), D-NAME (10 mg/ kg) or L-NAME (10 mg/kg) + L-arginine (600 mg /kg) was intravenously administered 15 min before LTD4 instillation. Data represent the mean ± S.E.M. of 8 to 12 animals. Open circle: non-sensitized -non-challenged, closed square: sensitized -challenged, striped square: sensitized -challenged -D-NAME-treated, open square: sensitized -challenged -L-NAME (3 mg /kg)-treated, light shaded square: sensitized -challenged -L-NAME (10 mg/kg)-treated, dark shaded square: sensitized -challenged -L-NAME (30 mg /kg)-treated, triangle (upside down): sensitized -challenged -L-arginine (600 mg /kg)-treated, triangle: sensitized -challenged -L-NAME (10 mg/kg) + L-arginine (600 mg/kg)-treated. *P<0.05, **P<0.01, compared to the sensitized -challenged group.
† † P<0.01, compared to the non-sensitized -non-challenged group. # P<0.05, compared to the sensitized -L-NAME-treated group. Table 2 . Influence of N M -nitro-L-arginine methyl ester (L-NAME) and L-arginine on baseline specific airway resistance (sRaw) of the sensitized -challenged guinea pig sRaw [cmH2O´ml/ (ml/ s)] Time (min) after drug administration 0 1 5
Sensitized -challenged -saline-administered 1.49 ± 0.05 1.58 ± 0.05
Sensitized -challenged -L-NAME-administered 1.52 ± 0.26
Sensitized -challenged -L-arginine-administered 1.50 ± 0.16 1.56 ± 0.10 L-NAME (10 mg/ kg, i.v.) or L-arginine (600 mg /kg, i.v.) was administered to the sensitized -challenged guinea pig. Data are the mean ± S.E.M. of 8 animals.
suppression of the sRaw elevation by LTD4 in the sensitized -challenged guinea pig. The inhibitory effect of L-NAME was significantly reversed by co-administration of L-arginine, although L-arginine alone showed no effect on the increase of sRaw induced by LTD4. The combination treatment with indomethacin (10 mg / kg, p.o.) and AA-861 (100 mg/ kg, i.p.) barely influenced the increased sRaw induced by LTD 4 instillation in the sensitized -challenged guinea pig (data not shown). Figure 9a shows the time-course change in sRaw after instillation of 10 -6 M SNP. SNP caused a prompt elevation of sRaw that peaked at 2 min, followed by diminution until 10 min after instillation. According to the results obtained, sRaw was measured 2 min after SNP instillation in the following experiments.
Nasal responsiveness to SNP
Nasal responsiveness to SNP of sensitized -challenged guinea pigs was evaluated 2 days after the 30th pollen challenge and compared to that of non-sensitized -non-challenged animals. No apparent differences in the concentration-related changes in sRaw were observed between the two groups (Fig. 9b) .
Amount of NO2
-and NO3 -in NCLF induced by LTD4 In the sensitized -challenged group, LTD4 application caused a significant increase in NO2
-and NO3 -in NCLF compared with that before treatment. On the other hand, these levels in the non-sensitized -non-challenged group showed only a slight tendency to increase in response to 10 . Amounts of NO2 -and NO3 -in nasal cavity lavage fluid (NCLF) induced by intranasal instillation of leukotriene (LT) D4 in the sensitized -challenged guinea pig. The experiment was performed 2 days after the 30th inhalation challenge. Three initial NCLs were performed to remove pre-existing NO2 -and NO3 -at 20-min intervals and the 3rd NCLF was used as a baseline (before). LTD4 (10 -8 M) was instilled 10 min after the 3rd NCL and the NCL was then performed 10 min after the LTD4 instillation. Data represent the mean ± S.E.M. of 7 to 9 animals. *P<0.05. NS: not significant.
LTD4. The increased production of NO2
-and NO3 -by LTD4 in the sensitized -challenged group was significantly larger than that in the non-sensitized -non-challenged group (Fig. 10) .
DISCUSSION
In the present experiments, sRaw was selected as the index of nasal obstructive response to intranasal instillation of LTD4. We consider that sRaw reflects total (upper and lower airway) airway resistance, because the guinea pig functionally respires through the nose but not through the mouth. The early bronchoconstrictor response is reportedly characterized by rapid and shallow breathing in a guinea pig asthma model (20) . We previously reported that the pollen inhalation challenge-induced elevation of sRaw correlated well with a decrease in respiratory frequency in our experimental allergic rhinitis model (11) . These reports indicate that allergic responses of the upper and lower airways are characteristically different in conscious guinea pigs. In our allergic rhinitis model, intranasal instillation of histamine and LTD 4 decrease respiratory frequency, whereas forced inhalation of a fine mist of histamine, approx. 80% of which was trapped in and acted on the bronchi, induces rapid and shallow breathing (S. Kohno et al., unpublished data). In addition, administration of LTD4, a well-known potent bronchoconstrictor, into the nasal cavities of the non-sensitized guinea pig produced no elevation of sRaw even at 10 -6 M. Furthermore, Narita et al. (21) reported that most Evans blue dye instilled intranasally was found within the nasal cavity. Thus, it can be concluded that the changes in sRaw induced by intranasal instillation of agonists in the present manner entirely reflect the nasal response (nasal airway patency) and not the lower airway response.
We previously reported that our allergic rhinitis model come to show nasal hyperresponsiveness to histamine (12) with the elevation of serum IgG1 and IgE levels by repetitive antigen inhalation challenges (11) . In the present study, we demonstrated that remarkable hyperresponsiveness to LTD4, which was much stronger than that to histamine, was observed using this model. In agreement with the features of the hyperresponsiveness to histamine (12) , the intensity of the nasal hyperresponsiveness to LTD4 increased with the number of antigen provocations in sensitized -challenged animals, and the hyperresponsiveness was evident at 10 h and on the 2nd day, but not on the 7th day after the pollen challenge. Thus, the hyperresponsiveness to these agonists might be acquired at least partly through the same mechanisms. Recent experiments revealed that the nasal hyperresponsiveness to histamine had occurred already 4 h after antigen inhalation challenge and that the amount of CysLTs in nasal cavity lavage fluid after antigen inhalation challenge showed a biphasic increase, the time of which corresponded to that of the biphasic sRaw elevation (M. Yamasaki et al., submitted manuscript). It appears that the former result is applicable in the case of the hyperresponsiveness to LTD4. Thus, the late sRaw elevation can be induced by the late production of CysLTs combined with the hyperresponsiveness. However, CysLTs hardly contributes to the early sRaw elevation, because the CysLT1-receptor antagonist did not influence it (Fig. 2) . On the other hand, Horwarth and Holgate (22) reported that an H1-receptor antagonist is effective for sneezing, itching and nasal secretion, but not for nasal blockage in allergic rhinitis patients. In accordance with the clinical results, mepyramine did not inhibit both the early and the late responses (Fig. 2) , but sneeze was significantly suppressed by the drug (data not shown) in our model, strongly suggesting that the model is potentially useful for research on allergic rhinitis. Since the early sRaw elevation was inhibited by neither the H 1 -nor the CysLT 1 -receptor antagonist as described above, other mediator(s) than histamine and CysLTs must take part in the elevation.
The exposure frequency-dependent increase and restoration pattern of nasal hyperresponsiveness closely resemble clinical allergic rhinitis. It is accepted that nasal hyperresponsiveness in patients diagnosed with perennial allergic rhinitis is more evident than that in individuals with seasonal rhinitis (23) . Furthermore, seasonal allergic rhinitis patients exhibit more marked nasal symptoms in the pollen season than in the off-season (24) . Consequently, we believe that our allergic rhinitis model of guinea pigs is effective in the research of detailed mechanisms of the induction of nasal hyperresponsiveness.
In terms of the pathophysiological action of LTD4 on nasal mucosa, LTD4 induces dilatation of nasal capacitance blood vessels and increases nasal capillary permeability. We evaluated the contribution of nasal blood vessel dilatation to the LTD4-induced elevation of sRaw in the sensitized -challenged animal using naphazoline, a potent vasoconstrictive a-agonist. The result showed that the drug appeared to completely suppress the increase in sRaw by LTD4 and lowered sRaw to below spontaneous levels. Therefore, it was strongly suggested that the blood vessel dilatation was directly involved in the sRaw elevation induced by LTD4, which prompted us to examine LTD4-induced changes in nasal mucosal blood vessels using a stereoscopic microscope. Microscopy demonstrated that superficial veins of 50 to 80 m m in diameter, which are occasionally located in the upper stream of capacitance blood vessels, dilated immediately in response to LTD4. This dilatation of the upper stream vein strongly suggests progressive distension of the venous sinusoid forming the capacitance vessels, which are reported to mainly reflect nasal patency (25) . In the present study, maximum dilata-tion occurred at 10 min after LTD4 application, which was identical to that recorded for maximum sRaw induced by LTD4. From these results, it can be concluded that nasal blood vessel dilatation largely contributes to the sRaw elevation by instilled LTD4, and the results explain why naphazoline potently lowered the elevated sRaw by LTD4.
Next, we examined whether the elevation of sRaw induced by intranasal instillation of LTD4 is induced via CysLT1-receptor stimulation. Pranlukast (30 mg/ kg, p.o.), a CysLT1-receptor antagonist, was administered at a dose that specifically inhibits bronchoconstrictive responses induced by CysLTs, but not those by other agonists in guinea pigs in vivo (26) , and was found to strongly inhibit the response. Consequently, the dilatation of nasal blood vessels induced by LTD 4 is solely mediated by CysLT1-receptor activation.
LTD4-induced dilatation of nasal blood vessels by CysLT1-receptor activation is potentially induced by two distinct endogenous substances, which are the products of the L-arginine enzymatic pathway and the metabolites of arachidonic acid via the COX enzymatic pathway. The increase in sRaw by LTD4 was potently blocked by an NO synthase (NOS) inhibitor, L-NAME, and the inhibitory effect of L-NAME was completely reversed by the coadministration of the substrate for NOS, L-arginine. On the other hand, the combination treatment with COX inhibitor, indomethacin, and 5-LO inhibitor, AA-861, had no inhibitory effect on the response. These results suggest that intranasally instilled LTD4 mainly induces the increase in sRaw by NO, and not metabolites of arachidonic acid, through the activation of CysLT1-receptors on the surface of the endothelial cells of nasal blood vessels. LTD4 instillation caused a significant increase in NO2
-and NO3 -in NCLF compared with that before LTD4 instillation in the sensitized-challenged guinea pig, but not in the non-sensitizednon-challenged animal; and the dose-sRaw elevation curve of nasal SNP, an NO donor, in the sensitized-challenged animal was almost equivalent to that in the non-sensitizednon-challenged group. Therefore, it is conceivable that nasal vessel dilatation by LTD4 results from the acquired hyperproduction of NO from the vascular endothelial cells and not from the direct action of LTD4 on the vascular smooth muscle cells themselves. As is well known, NO produced by constitutive NOS induces relaxation of the smooth muscle cells through an activation of cytosolic guanylate cyclase and an increase in the intracellular guanosine 3',5'-cyclic monophosphate level.
Although NO is known to be a powerful vasodilator and to control the filling of nasal capacitance vessels (27) , baseline sRaw was not affected by L-NAME, which is in contrast to the effect of naphazoline. Based upon the present study's result and a report that L-NAME did not change nasal airway resistance from baseline in healthy subjects (28) , NO may not substantially act as a vasodilator in nasal airways under unstimulated conditions.
On the other hand, the extent of the naphazoline-induced decrease in sRaw in the sensitized -challenged -LTD4-treated animal, particularly at 40 min after LTD4 instillation, was smaller than that of the non-sensitized -nonchallenged -and sensitized -challenged -LTD4-non-treated groups. Furthermore, a moderate increment of sRaw by LTD4 was still detected at 120 min after the provocation, whereas the LTD4-induced dilatation of nasal blood vessels was completely restored to a normal level at 40 min. In light of these observations, we investigated whether nasal vascular permeability continues to accelerate at 40 min after LTD4 instillation. Results showed that the stimulatory effect had ceased. On the other hand, at 10 min, a small but significant amount of plasma was exudated (increased plasma exudation volume was approximately 40 ml / nostril when calculated from the Evans blue concentration of the plasma). Therefore, we hypothesize that the vascular permeability response may be a minor contributor to early sRaw elevation (10 min) induced by LTD 4, but nasal capillary permeability is not involved at a relatively late period (40 min or later). LTD4 instillation into the nasal cavities of allergic rhinitis patients has been reported to cause an increase in nasal secretion (7) . During the present experiments, we found that viscous secreted material had accumulated intranasally in the sensitized -challenged -LTD4-treated guinea pig but not in the non-sensitizedchallenged -LTD4-treated animals, although at present we cannot quantitatively measure this secretion. Thus, LTD4 may contribute to a persistent increase in sRaw on the basis of the enhanced secretion.
In conclusion, we demonstrated that repetitive exposure of sensitized -challenged guinea pigs to cedar pollen results in remarkable but reversible hyperresponsiveness to LTD4. Hyperresponsiveness in sensitized -challenged animals is mainly due to an increased dilatative response of the nasal blood vessels to the agonist, which can be related to hyperproduction of NO.
